Stimulus-elicited genomic profile markers of a neurodegenerative condition
AssigneeBlanchette Rockefeller Neurosciences Drive
InventorsDaniel L. Alkon, Tapan K. Khan
Life of this patent
Estimating the term…
Loading patent…
AssigneeBlanchette Rockefeller Neurosciences Drive
InventorsDaniel L. Alkon, Tapan K. Khan
Estimating the term…
The present disclosure is directed to methods of diagnosing a neurodegenerative condition, such as Alzheimer's disease, comprising contacting a cell sample from a subject with at least one stimulus, such as a protein and/or polysaccharide mixture, a protein kinase C activator, an Aβ oligomer, an agent, and combinations thereof; and detecting the expression of at least one gene in the cell sample. Methods may further comprise comparing the expression of the at least one gene in the cell sample to the expression of the same at least one gene in control cells; and determining whether the subject has the neurodegenerative condition (e.g., Alzheimer's disease), wherein a change in the expression of the at least one gene in the cell sample compared to the expression of the same at least one gene in the control cells indicates the subject has the neurodegenerative condition (e.g., Alzheimer's disease).
A method of diagnosing a neurodegenerative condition in a subject in need thereof comprising:
A method of diagnosing a neurodegenerative condition in a subject in need thereof comprising:
A method of screening for a compound useful for the development of one or more drug candidates for the treatment or prevention of a neurodegenerative condition comprising:
A kit for diagnosing a neurodegenerative condition comprising an extracellular matrix preparation, and control cells from at least one individual without the neurodegenerative condition.
Dependencies are inferred from the claim text.